1Apple F S, Panteghini M, Ravkilde J, et al. Qualityspecifications for B-type natriuretic peptide assays [ J ]. Clin Chem, 2005,51 : 486- 493.
2Bossuyt P M, Reitsma J B, Bruns D B, et al. The STARD statement for reporting of diagnostic accuracy: explanation and elaboration[ J]. Clin Chem, 2003, 49: 7-18.
3Maisel A S, Krishnaswamy P, Nowak R M, et al. for the BNP Multinational Study Investigators. Rapid measurement of B-type natriuetic peptide in the emergency diagnosis of heart failure [ J ]. N Engl J Med, 2002, 347 : 161-167.
4Brandt I, Lambeir A M, Ketelslegers J M, et al. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form[ J]. Clin Chem, 2006,52:82-87.
5Shimizu H, Masuta K, Asada H, et al. Characterization of molecular forms of probrain natriuretic peptide in human plasma[ J ]. Clin Chim Acta, 2003,334:233-239.
6Panteghini M, Clerico A. Cardiac natriuretic hormones as markers of cardiovascular disease: methodological aspects [ J ]. In : Clerieo A, Emdin M, eds. Natriuretie peptides. The hormones of the heart. Springer: Berlin, 2006, 65-89.
7Giuliani I, Rieunier F, Larue C, et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood [ J ]. Clin Chem, 2006,52: 1054-1061.
8Liang F, O' Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coil Cardiol, 2007; In press; first access as doi: 10. 1016/j/jacc. 2006.10. 063.
9Schellenberger U, ORear J, Guzzetta A, et al. The precursor to B-type natriuretic peptide is an O-linked glycoprotein [ J ]. Arch Biochem Biophys, 2006,451 : 160-166.
10Seferian K R ,Tamm N T, Semenov A G, et al. The BNp precursor is the major immunoreactive form of BNP in patients with heart failure[J]. Clin Chem, 2007,53:866-873.
同被引文献11
1CLSI EP15-A2. User demonstration of performance for precision andaccuracy; Approved guideline-second Edition ( EP15-A2 ) [ S ]. Wayne : CLS1,2004.
2CLSI EP17-A. Protocols for Determination of Limits of Detection and Limits of Quantitation ; Approved Guideline ( EP17-A ) [ S ]. Wayne : CLSI, 2004.
3CLSI EP6-A. User demonstration of performance for precision and ac- curacy ; Approved Guideline (EP6-A) [ S ]. Wayne : CLS1,2004.
4CLSI EP7-A2. Interference testing in clinical chemistry; Approved Guideline-second Edition ( EP7-A2 ) [ S ]. Wayne : CLSI,2005.
5Wu AH, Packer M, Smith A, et al. Analytical and clinical evalua- tion of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study [ J ]. Clin Chem,2004,50(5):867-873.
6Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays [ J]. Am J Clin Pathol, 2005,123 (3) :439-445.
7Wians FH Jr, Wilson BA, Grant A, et al. Evaluation of the analyti- cal performance characteristics of the Bayer ACS: 180 R B-type na- triuretic peptide (BNP) assay[ J]. Clin Chim Acta, 2005, 353 ( 1- 2) : 147-155.
8Prontera C, Zaninotto M, Giovannini S, et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the Car- dioOrmocheck study [ J ]. Clin Chem Lab Med, 2009, 47 (6) : 762-768.
